1 Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
2 Clinical Center of Vojvodina, Novi Sad, Serbia.
Aust N Z J Psychiatry. 2017 Sep;51(9):886-896. doi: 10.1177/0004867417695889. Epub 2017 Apr 12.
Distinguished authors in the field have repeatedly alerted psychiatrists of the alarming trends in the treatment of bipolar disorders: decline of lithium use, paralleled by the increase of prescribing anticonvulsants and second-generation antipsychotic drugs. Research has been conducted in order to explore the factors that led to this development and to provide arguments for the need to reverse this trend.
This paper represents a narrative review of the literature containing retrieved research articles focusing on the efficacy of lithium. The papers included in this overview were published prior to June 2016; additional papers were identified by searching the reference lists of reviewed articles. Taking into account the amount of literature available, no search can be exhaustive; on the other hand, the studies consulted, all of which explore the effectiveness of various compounds, may have their own limitations as well.
The evidence of the effectiveness of lithium in the treatment of acute mania, acute bipolar depression and the prevention of manic and depressive episodes is compelling. Lithium is the most effective augmentation agent in treatment-resistant depression. Its anti-suicidal effects are well established. The neuroprotective effects of lithium have been demonstrated in case-control studies and in population-based research. It has been established that starting lithium early in the course of the disorder reduces the rates of treatment non-response.
Despite abundant evidence regarding the efficacy of lithium and its effectiveness in the treatment of bipolar disorders, its use is declining at the beginning of the 21st century. It is of paramount importance to keep reminding psychiatrists and educating physicians about the unique properties of lithium and about monitoring patients treated with lithium, since it has been suggested that lithium should once again become the first-line treatment for bipolar disorders.
该领域的杰出作者多次提醒精神科医生注意双相情感障碍治疗中令人震惊的趋势:锂的使用减少,同时抗惊厥药和第二代抗精神病药物的处方增加。已经进行了研究,以探讨导致这种发展的因素,并为扭转这一趋势提供论据。
本文是对文献的叙述性综述,其中包含了针对锂疗效的研究文章。本文综述中包含的论文发表于 2016 年 6 月之前;通过检索已审查文章的参考文献列表,还确定了其他一些论文。考虑到可用文献的数量,任何搜索都不可能是详尽无遗的;另一方面,所咨询的研究,所有这些研究都探讨了各种化合物的有效性,也可能有其自身的局限性。
锂在治疗急性躁狂症、急性双相抑郁症和预防躁狂和抑郁发作方面的有效性的证据令人信服。锂是治疗抵抗性抑郁症最有效的增效剂。其抗自杀作用已得到证实。锂的神经保护作用已在病例对照研究和基于人群的研究中得到证实。已经确定,在疾病过程的早期开始使用锂可以降低治疗无反应的发生率。
尽管有大量关于锂的疗效及其在双相情感障碍治疗中的有效性的证据,但在 21 世纪初,锂的使用正在减少。至关重要的是要不断提醒精神科医生并教育医生关于锂的独特特性,以及监测接受锂治疗的患者,因为有人建议锂应该再次成为双相情感障碍的一线治疗方法。